The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC).
P. Klare
No relevant relationships to disclose
F. G. Foerster
No relevant relationships to disclose
M. Geberth
Honoraria - Roche
Research Funding - Roche
A. Schneeweiss
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
H. Tesch
Consultant or Advisory Role - GlaxoSmithKline; Hexal; Novartis; Pfizer; Roche; Sanofi
Honoraria - GlaxoSmithKline; Hexal; Novartis; Pfizer; Roche; Sanofi
S. Kuemmel
No relevant relationships to disclose
C. Schumacher
No relevant relationships to disclose
W. Hollburg
No relevant relationships to disclose
U. Soeling
No relevant relationships to disclose
M. Schmidt
Stock Ownership - Roche
Honoraria - GlaxoSmithKline; Roche